Form 4: Elanco CFO Acquires Deferred Stock Units

Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, acquired 7.5552 deferred stock units, increasing his beneficial ownership.

Summary

• Robert M. VanHimbergen, Executive Vice President and Chief Financial Officer of Elanco Animal Health Inc. (ELAN), reported an acquisition of deferred stock units.
• The transaction involved the acquisition of 7.5552 Deferred Stock Units (DSUs) on February 6, 2026.
• Each DSU represents the right to receive one share of Company common stock or its cash equivalent.
• The price of the derivative security (DSU) was $25.2.
• Following this transaction, Mr. VanHimbergen beneficially owns 23.4702 derivative securities.
• The DSUs are set to settle in cash or shares of Company common stock upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While the transaction size is relatively small, an executive's acquisition of company equity generally indicates confidence in future performance and aligns management interests with shareholders.

Positives

• The acquisition of deferred stock units by a key executive like the CFO signals confidence in the company's future performance.
• This transaction aligns the executive's financial interests with those of the shareholders, as the value of DSUs is tied to the company's stock performance.

Future Outlook

The acquired deferred stock units are scheduled to settle in cash or shares of Elanco common stock following the termination of employment or during a specified future year, in accordance with the company's Executive Deferral and Stock Match Plan.

Industry Context

StockSavvy.ai notes that insider transactions, such as the acquisition of deferred stock units by a CFO, are often viewed by investors as a positive signal, indicating management's belief in the company's future prospects. This aligns with common practices in executive compensation within the pharmaceutical and animal health sectors, where equity-based incentives are used to retain talent and align interests.

Comparison to Industry Standards

• The use of Deferred Stock Units (DSUs) as part of executive compensation is a standard practice across many industries, including the animal health sector, to incentivize long-term performance and retention.
• The specific number of units acquired and their value are typical for routine executive compensation grants rather than a significant open-market purchase, making direct comparisons to specific company projects or large-scale industry transactions less relevant.

Stakeholder Impact

• Shareholders: The transaction aligns the financial interests of a key executive with those of shareholders, potentially fostering greater confidence in management's commitment to long-term value creation.
• Employees: The Executive Deferral and Stock Match Plan, under which these units were granted, is part of the company's broader compensation strategy, which can impact employee retention and motivation.

Next Steps

• Settlement of the Deferred Stock Units will occur upon termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Key Dates

Recommendation

A seasoned investor would likely view this insider acquisition as a positive, albeit minor, indicator of management confidence. While not a strong enough signal on its own to warrant a 'buy' recommendation, it reinforces a 'hold' position by suggesting that the company's leadership believes in its future prospects and is aligning their personal financial interests with the company's performance.

Keywords

Elanco, ELAN, Form 4, Insider Transaction, Deferred Stock Units, Executive Compensation, Robert M. VanHimbergen, Animal Health